2. Search Result
Search Result
Results for "

( )-C75

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

4

Recombinant Proteins

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12364
    C75
    20+ Cited Publications

    		 Fatty Acid Synthase (FASN) Cancer
    C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM . C75 is a potent CPT1A activator .
    C75
  • HY-12364A
    trans-C75

    (±)-C75

    		 Fatty Acid Synthase (FASN) Cancer
    trans-C75 ((±)-C75) is an enantiomer of C75. C75 is a synthetic fatty-acid synthase (FASN) inhibitor.
    trans-C75
  • HY-12364C
    (+)-trans-C75

    (+)-C75

    		 Mitochondrial Metabolism Others
    (+)-trans-C75 ((+)-C75) is an enantiomer of C75 (HY-12364) (a fatty acid synthase inhibitor). (+)-trans-C75 is less potent than the racemic mixture or the (-) enantiomer in enhancing the cancer-killing ability of ionizing radiation. (+)-trans-C75 inhibits CPT1 and is an anorectic agent .
    (+)-trans-C75
  • HY-12364B
    (−)-C75

    		Fatty Acid Synthase (FASN) Cancer
    (−)-C75 is a isoform of C75 (HY-12364), which is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM . C75 is a potent CPT1A activator .
    (−)-C75
  • HY-157084
    HS-291

    		ROS Kinase Bacterial Infection
    HS-291 is a HtpG inhibitor of Borrelia burgdorferi (Bb). HS-291 contains BX-2819 (high affinity for Bb HtpG), PEG linker, and Verteporfin (HY-B0146) (a photoactive toxin).HS-291 produces reactive oxygen species under light activation to oxidize HtpG and a discrete protein subset near chaperone proteins and can quickly and irreversibly inactivate Bb .
    HS-291
  • HY-15042
    MK 0686

    		Bradykinin Receptor Metabolic Disease
    MK 0686, a potent bradykinin B1 receptor antagonist, demonstrates autoinduction of metabolism in rhesus monkeys after oral administration. It undergoes significant biotransformation primarily via oxidation pathways, leading to the formation of metabolites like M11 and M13 in rhesus liver microsomes. This metabolic induction is mediated by CYP2C75, as evidenced by increased mRNA expression, protein levels, and catalytic activity of this enzyme in hepatocytes and liver microsomes from MK 0686-treated animals. The autoinduction phenomenon suggests that MK 0686 enhances its own metabolism by upregulating CYP2C75, potentially influencing its systemic exposure and pharmacokinetics over time .
    MK 0686
  • HY-141648
    Antibacterial agent 219

    		Bacterial Infection
    Antibacterial agent 219 (Compound 2/75c) exhibits antibacterial activity by targeting cell wall biosynthesis. Antibacterial agent 219 inhibits methicillin-resistant Staphylococcus aureus (MRSA) strains (MIC=0.5-32 µg/mL), Enterococcus faecium (MIC=2 µg/mL) and S. aureus (MIC=2 µg/mL) .
    Antibacterial agent 219

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: